AMPE News and Press, Ampio Pharmaceuticals Inc. From 02/24/21

Ampio Pharmaceuticals, Inc. to Report Annual 2020 Financial Results and Provide Corporate Business Update PR Newswire ENGLEWOOD, Colo. , Feb. 24, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the adv...

Ampio Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion Additional study sites will accelerate patient enrollment. Preliminary data shows Ampion improves all-cause mortality. PR Newswire ENGLEWOOD, Colo. , Feb. 23, 2021 ...

Ampio Pharmaceuticals, Inc. to Present at Upcoming Investor Conference Corporate Presentation to be Webcast on February 17, 2021 PR Newswire ENGLEWOOD, Colo. , Feb. 16, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmace...

Ampio Pharmaceuticals, Inc. is a non-revenue producing biopharmaceutical company aiming to develop immunology-based therapies for inflammatory conditions. Ampio's pipeline consists of one late-stage therapeutic ("Ampion") across six inflammatory indications. Ampion is a novel bio...

Ampio Pharma (AMPE) announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion vs standard of care for patients with COVID-19 respiratory distress (AP-014).An independent statistical analysis revealed patients admin...

Ampio Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in COVID-19 Respiratory Distress - Subjects who received Ampion treatment required less oxygen than standard of care alone. - Subjects who received Ampion treatment were stable or had improvement on the O...

Biopharmaceutical company Ampio Pharmaceuticals (AMPE) announces that its ongoing U.S. Phase I clinical trial for inhalation treatment of COVID-19 with Ampion (AP-014) is 55% enrolled.Inhaled Ampion specifically targets inflammation in the lung and is currently being inves...

Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled PR Newswire ENGLEWOOD, Colo. , Jan. 14, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE), a biopharmaceutical company ...

Ampio Pharmaceuticals (AMPE) has launched a global clinical trial for the IV formulation of its lead asset Ampion for treating COVID-19 patients including in out-patient settings. It has also provided updates on Phase I clinical trial for the inhaled formulation of the Ampion curren...

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients PR Newswire ENGLEWOOD, Colo. , Jan. 4, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancem...